|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemistry confirmed the up-regulation of SELL and down-regulation of IGFBP6 in nodal metastasis relative to primary tumours.
|
18213732 |
2008 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The cell cycle of tumor cells was detected by flow cytometry, while Transwell assay was used to quantify the invasion and migration of tumor cells after IGFBP-6 intervention.
|
29439316 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, IGFBP-6 mRNA expression was associated with tumor invasion (tumor size) and the IGFBP-6 protein level was associated with nodal status.
|
27644646 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, exogenous expression of IGFBP6 inhibited CNE2 cell proliferation and invasion in vitro.
|
27623076 |
2016 |
|
Neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Among the genes in the turquoise module, COL5A2 (collagen, type V, alpha 2) could be regulated by PBX (pre-B-cell leukemia homeobox 1)1/2 and HOXB1(homeobox B1) transcription factors to be involved in the focal adhesion pathway; CENP-E (centromere protein E, 312kDa) by E2F4 (E2F transcription factor 4, p107/p130-binding); MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived [avian]) by PAX5 (paired box 5); and BCL-2 (B-cell CLL/ lymphoma 2) and IGFBP-6 (insulin-like growth factor binding protein 6) by GLI1.
|
23167388 |
2012 |
|
Central neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Among the genes in the turquoise module, COL5A2 (collagen, type V, alpha 2) could be regulated by PBX (pre-B-cell leukemia homeobox 1)1/2 and HOXB1(homeobox B1) transcription factors to be involved in the focal adhesion pathway; CENP-E (centromere protein E, 312kDa) by E2F4 (E2F transcription factor 4, p107/p130-binding); MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived [avian]) by PAX5 (paired box 5); and BCL-2 (B-cell CLL/ lymphoma 2) and IGFBP-6 (insulin-like growth factor binding protein 6) by GLI1.
|
23167388 |
2012 |
|
Childhood Neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Among the genes in the turquoise module, COL5A2 (collagen, type V, alpha 2) could be regulated by PBX (pre-B-cell leukemia homeobox 1)1/2 and HOXB1(homeobox B1) transcription factors to be involved in the focal adhesion pathway; CENP-E (centromere protein E, 312kDa) by E2F4 (E2F transcription factor 4, p107/p130-binding); MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived [avian]) by PAX5 (paired box 5); and BCL-2 (B-cell CLL/ lymphoma 2) and IGFBP-6 (insulin-like growth factor binding protein 6) by GLI1.
|
23167388 |
2012 |
|
Neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
This study therefore shows that IGFBP-6 plays a role in neuroblastoma cell growth in vivo and in vitro and that stable overexpression of IGFBP-6 leads to alteration of the initial balance between the IGFBPs.
|
11874695 |
2002 |
|
Central neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
This study therefore shows that IGFBP-6 plays a role in neuroblastoma cell growth in vivo and in vitro and that stable overexpression of IGFBP-6 leads to alteration of the initial balance between the IGFBPs.
|
11874695 |
2002 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Instead, IGFBP-6 appears to have an importance for the characteristics of edema and brain invasion in meningiomas.
|
12125963 |
2002 |
|
Childhood Neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
This study therefore shows that IGFBP-6 plays a role in neuroblastoma cell growth in vivo and in vitro and that stable overexpression of IGFBP-6 leads to alteration of the initial balance between the IGFBPs.
|
11874695 |
2002 |
|
Neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Since IGFBP-6 secretion is associated with the arrest of proliferation in neuroblastoma cells and is regulated by the combined actions of differentiation factors, we subcloned the proximal promoter of human IGFBP-6 (nt -766/+1) into a pCAT expression vector so as to examine modulation of its transcriptional activity.
|
11161966 |
2000 |
|
Central neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Since IGFBP-6 secretion is associated with the arrest of proliferation in neuroblastoma cells and is regulated by the combined actions of differentiation factors, we subcloned the proximal promoter of human IGFBP-6 (nt -766/+1) into a pCAT expression vector so as to examine modulation of its transcriptional activity.
|
11161966 |
2000 |
|
Childhood Neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Since IGFBP-6 secretion is associated with the arrest of proliferation in neuroblastoma cells and is regulated by the combined actions of differentiation factors, we subcloned the proximal promoter of human IGFBP-6 (nt -766/+1) into a pCAT expression vector so as to examine modulation of its transcriptional activity.
|
11161966 |
2000 |
|
Neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings show that IGFBP-6 influences neuroblastoma cell growth, both in vitro and in experimental xenograft development.
|
9563481 |
1998 |
|
Central neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings show that IGFBP-6 influences neuroblastoma cell growth, both in vitro and in experimental xenograft development.
|
9563481 |
1998 |
|
Childhood Neuroblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings show that IGFBP-6 influences neuroblastoma cell growth, both in vitro and in experimental xenograft development.
|
9563481 |
1998 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Finally, we discuss the role of IGFBP-6 in autoimmune disease and how novel mechanistic insights could lead to exploit thermal stress-related mechanisms in the context of cancer therapy.
|
30117676 |
2018 |
|
Glioma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We determined that in human glioma tissue, glioma cell lines, and patient-derived xenograft cell lines, treatment with TMZ enhances the expression of IGF1 receptor (IGF-1R) and IGF2 and decreases the expression of IGFBP6, which sequesters IGF2.
|
30231881 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Finally, we discuss the role of IGFBP-6 in autoimmune disease and how novel mechanistic insights could lead to exploit thermal stress-related mechanisms in the context of cancer therapy.
|
30117676 |
2018 |
|
Glioma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Together our findings suggest that IGFBP6 might be an important regulator and prognostic factor for glioma.
|
27650075 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor (IGF)-binding protein (IGFBP)-6 decreases cancer cell proliferation and survival by inhibiting the effects of IGF-II.
|
24003225 |
2013 |
|
Rhabdomyosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Importantly, PHB2 knockdown completely abolished IGFBP-6-mediated RMS cell migration.
|
24003225 |
2013 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor (IGF)-binding protein (IGFBP)-6 decreases cancer cell proliferation and survival by inhibiting the effects of IGF-II.
|
24003225 |
2013 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6.
|
17519236 |
2007 |